CoverageForm 410-K10-Q8-K13D13G13F

VIRI Virios Therapeutics, Inc. - 8-K

Filed Mar 26, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001104659-26-034928
7.019.01

Item 7.01 - Regulation FD Disclosure

131 words

Item 7.01

Regulation FD Disclosure.

On March 26, 2026, the Company posted a shareholder letter to its website providing a corporate update. A copy of the shareholder letter is furnished as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information in the shareholder letter attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

​

​

Item 9.01 - Financial Statements and Exhibits

51 words

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits .

​

​

​

​

Exhibit Number

​ ​ ​

Description

99.1

​

Shareholder letter , dated March 26, 2026 (furnished herewith).

104

​

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

2